Cencora, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.

About COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. 

CEO
Robert P. Mauch
CEORobert P. Mauch
Employees
51,000
Employees51,000
Headquarters
Conshohocken, Pennsylvania
HeadquartersConshohocken, Pennsylvania
Founded
1947
Founded1947
Employees
51,000
Employees51,000

COR Key Statistics

Market cap
58.57B
Market cap58.57B
Price-Earnings ratio
22.82
Price-Earnings ratio22.82
Dividend yield
0.78%
Dividend yield0.78%
Average volume
1.24M
Average volume1.24M
High today
$310.89
High today$310.89
Low today
$304.31
Low today$304.31
Open price
$309.40
Open price$309.40
Volume
1.01M
Volume1.01M
52 Week high
$377.54
52 Week high$377.54
52 Week low
$244.82
52 Week low$244.82

Stock Snapshot

As of today, Cencora, Inc.(COR) shares are valued at $306.92. The company's market cap stands at 58.57B, with a P/E ratio of 22.82 and a dividend yield of 0.78%.

As of 2026-09-27, Cencora, Inc.(COR) stock has fluctuated between $304.31 and $310.89. The current price stands at $306.92, placing the stock +0.9% above today's low and -1.3% off the high.

Cencora, Inc.(COR) shares are trading with a volume of 1.01M, against a daily average of 1.24M.

In the last year, Cencora, Inc.(COR) shares hit a 52-week high of $377.54 and a 52-week low of $244.82.

In the last year, Cencora, Inc.(COR) shares hit a 52-week high of $377.54 and a 52-week low of $244.82.

COR News

TipRanks 2d
Cencora Adds Independent Director to Support Growth Strategy

An update from Cencora ( (COR) ) is now available. On September 24, 2026, Cencora’s Board of Directors elected Robert E. Sanchez as a new independent director,...

TipRanks 2d
Cencora appoints Robert Sanchez to board of directors

Cencora (COR) announced that its Board of Directors has elected Robert Sanchez as a new independent director, effective October 1. Sanchez is the Executive Chai...

Simply Wall St 4d
Cencora Conference Updates Keep Undervalued Case In Focus

Cencora (COR) is back on investor calendars after management spoke at back to back healthcare conferences in New York, outlining its focus on specialty pharmace...

Cencora Conference Updates Keep Undervalued Case In Focus

Analyst ratings

68%

of 19 ratings
Buy
68.4%
Hold
31.6%
Sell
0%

More COR News

Nasdaq 6d
Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027

Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology an...

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027
Nasdaq 6d
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation pri...

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

People also own

Based on the portfolios of people who own COR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.